Identification

Name
Methadone
Accession Number
DB00333  (APRD00485)
Type
Small Molecule
Groups
Approved
Description

A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of morphine. It also has a depressant action on the cough center and may be given to control intractable cough associated with terminal lung cancer. Methadone is also used as part of the treatment of dependence on opioid drugs, although prolonged use of methadone itself may result in dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3).

In Australia methadone is a Schedule 8 (controlled) drug.

Structure
Thumb
Synonyms
  • (+-)-Methadone
  • (+/-)-Methadone
  • (±)-methadone
  • 6-Dimethylamino-4,4-diphenyl-3-heptanone
  • dl-Methadone
  • Metadona
  • Methadonum
Product Ingredients
IngredientUNIICASInChI Key
Methadone hydrochloride229809935B1095-90-5FJQXCDYVZAHXNS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
DisketsTablet40 mg/1OralWest-Ward Pharmaceuticals Corp.1973-03-14Not applicableUs
DolophineTablet10 mg/1OralWest-Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
DolophineTablet5 mg/1OralWest-Ward Pharmaceuticals Corp.1947-08-13Not applicableUs
MetadolTablet5 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolTablet25 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolTablet1 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolTablet10 mgOralPaladin Labs Inc2003-07-29Not applicableCanada
MetadolSolution1 mgOralPaladin Labs Inc2003-07-11Not applicableCanada
MetadolSolution10 mgOralPaladin Labs Inc2000-05-05Not applicableCanada
Metadol-DSolution1 mgOralPaladin Labs Inc2014-08-18Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methadone HydrochlorideTablet10 mg/1OralLake Erie Medical Dba Quality Care Produts Llc2010-10-112014-12-31Us
Methadone HydrochlorideTablet5 mg/1OralSpecGx LLC2009-05-19Not applicableUs
Methadone HydrochlorideConcentrate10 mg/1mLOralRoxane Laboratories1988-04-30Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralGlenmark Pharmaceuticals Inc.,Usa2018-08-06Not applicableUs
Methadone HydrochlorideTablet5 mg/1OralBlenheim Pharmacal, Inc.2008-05-292010-08-31Us
Methadone HydrochlorideTablet10 mg/1OralVistapharm, Inc.1998-05-29Not applicableUs
Methadone HydrochlorideTablet10 mg/1OralCore Pharma, Llc2015-08-182015-08-18Us
Methadone hydrochlorideTablet10 mg/1001OralSun Pharmaceutical Industries Limited2018-04-17Not applicableUs
Methadone HydrochlorideInjection, solution10 mg/1mLIntramuscular; Intravenous; SubcutaneousAkorn2017-10-30Not applicableUs
Methadone HydrochlorideTablet10 mg/1Oralbryant ranch prepack2015-09-15Not applicableUs
International/Other Brands
Adolan / Depridol / Heptadon / Heptanon / Ketalgin / Mephenon / Physeptone / Polamidon
Categories
UNII
UC6VBE7V1Z
CAS number
76-99-3
Weight
Average: 309.4452
Monoisotopic: 309.209264491
Chemical Formula
C21H27NO
InChI Key
USSIQXCVUWKGNF-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO/c1-5-20(23)21(16-17(2)22(3)4,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6-15,17H,5,16H2,1-4H3
IUPAC Name
6-(dimethylamino)-4,4-diphenylheptan-3-one
SMILES
CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C1=CC=CC=C1

Pharmacology

Indication

For the treatment of dry cough, drug withdrawal syndrome, opioid type drug dependence, and pain.

Associated Conditions
Associated Therapies
Pharmacodynamics

Methadone is a synthetic opioid analgesic with multiple actions quantitatively similar to those at morphine, the most prominent of which involve the central nervous system and organs composed of smooth muscle. However, Methadone is more active and more toxic than morphine. Methadone is indicated for relief of severe pain, for detoxification treatment of narcotic addiction, and for temporary maintenance treatment of narcotic addiction. The principal actions of therapeutic value are analgesia and sedation and detoxification or temporary maintenance in narcotic addiction. The Methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe.

Mechanism of action

Methadone is a mu-agonist; a synthetic opioid analgesic with multiple actions qualitatively similar to those of morphine, the most prominent of which involves the central nervous system and organs composed of smooth muscle. The principal therapeutic uses for methadone are for analgesia and for detoxification or maintenance in opioid addiction. The methadone abstinence syndrome, although qualitatively similar to that of morphine, differs in that the onset is slower, the course is more prolonged, and the symptoms are less severe. Some data also indicate that methadone acts as an antagonist at the N-methyl-D-aspartate (NMDA) receptor. The contribution of NMDA receptor antagonism to methadone's efficacy is unknown. Other NMDA receptor antagonists have been shown to produce neurotoxic effects in animals.

TargetActionsOrganism
AMu-type opioid receptor
agonist
Human
AGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
ANeuronal acetylcholine receptor subunit alpha-10
antagonist
Human
ADelta-type opioid receptor
agonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
ULymphocyte antigen 96Not AvailableHuman
UAlpha-1-acid glycoprotein 2Not AvailableHuman
Absorption

Well absorbed following oral administration. The bioavailability of methadone ranges between 36 to 100%.

Volume of distribution
  • 1.0 to 8.0 L/kg
Protein binding

In plasma, methadone is predominantly bound to α1-acid glycoprotein (85% to 90%).

Metabolism

Hepatic. Cytochrome P450 enzymes, primarily CYP3A4, CYP2B6, and CYP2C19 and to a lesser extent CYP2C9 and CYP2D6, are responsible for conversion of methadone to EDDP and other inactive metabolites, which are excreted mainly in the urine.

Route of elimination

The elimination of methadone is mediated by extensive biotransformation, followed by renal and fecal excretion. Unmetabolized methadone and its metabolites are excreted in urine to a variable degree.

Half life

24-36 hours

Clearance
  • 1.4 to 126 L/h
Toxicity

In severe overdosage, particularly by the intravenous route, apnea, circulatory collapse, cardiac arrest, and death may occur.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Methadone Metabolism PathwayDrug metabolism
Methadone Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe metabolism of (R)-warfarin can be increased when combined with Methadone.
(S)-WarfarinThe metabolism of (S)-Warfarin can be increased when combined with Methadone.
1,10-PhenanthrolineThe therapeutic efficacy of Methadone can be decreased when used in combination with 1,10-Phenanthroline.
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when Methadone is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when Methadone is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when Methadone is combined with 3,4-Methylenedioxyamphetamine.
3,5-diiodothyropropionic acidThe metabolism of 3,5-diiodothyropropionic acid can be increased when combined with Methadone.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when Methadone is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be increased when combined with Methadone.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when Methadone is combined with 4-Methoxyamphetamine.
Food Interactions
  • Take without regard to meals. Avoid alcohol. Usually diluted in fruit juice.

References

Synthesis Reference

Charles J. Barnett, "Modification of methadone synthesis process step." U.S. Patent US4048211, issued August, 1952.

US4048211
General References
  1. Kell MJ: Utilization of plasma and urine methadone concentrations to optimize treatment in maintenance clinics: I. Measurement techniques for a clinical setting. J Addict Dis. 1994;13(1):5-26. [PubMed:8018740]
  2. Eap CB, Buclin T, Baumann P: Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence. Clin Pharmacokinet. 2002;41(14):1153-93. [PubMed:12405865]
  3. Joseph H, Stancliff S, Langrod J: Methadone maintenance treatment (MMT): a review of historical and clinical issues. Mt Sinai J Med. 2000 Oct-Nov;67(5-6):347-64. [PubMed:11064485]
  4. Connock M, Juarez-Garcia A, Jowett S, Frew E, Liu Z, Taylor RJ, Fry-Smith A, Day E, Lintzeris N, Roberts T, Burls A, Taylor RS: Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007 Mar;11(9):1-171, iii-iv. [PubMed:17313907]
  5. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL: Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction. 2005 Oct;100(10):1496-509. [PubMed:16185211]
External Links
Human Metabolome Database
HMDB0014477
KEGG Drug
D08195
KEGG Compound
C07163
PubChem Compound
4095
PubChem Substance
46505722
ChemSpider
3953
BindingDB
82507
ChEBI
6807
ChEMBL
CHEMBL651
Therapeutic Targets Database
DAP000267
PharmGKB
PA450401
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Methadone
ATC Codes
N07BC02 — MethadoneN02AC52 — Methadone, combinations excl. psycholeptics
AHFS Codes
  • 28:08.08 — Opiate Agonists
FDA label
Download (327 KB)
MSDS
Download (60 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingTreatmentPain, Acute1
1CompletedNot AvailableDrug withdrawal syndrome neonatal1
1CompletedNot AvailableHealthy Volunteers1
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Isavuconazole / Pharmacokinetics of Methadone1
1CompletedNot AvailableHepatitis C Viral Infection1
1CompletedNot AvailableInfections, Human Immunodeficiency Virus and Hepatitis1
1CompletedNot AvailableOpiate Withdrawal Syndrome1
1CompletedOtherHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
1CompletedSupportive CarePain NOS1
1CompletedTreatmentCocaine Abuse / Opioid Dependence1
1CompletedTreatmentCocaine-Related Disorders / Heroin Dependence / Human Immunodeficiency Virus (HIV)1
1CompletedTreatmentCocaine-Related Disorders / Opiate-Related Disorders1
1CompletedTreatmentHIV Risk Behaviors / Substance-Related Disorders1
1CompletedTreatmentHealthy Participants1
1CompletedTreatmentHealthy Volunteers3
1CompletedTreatmentHepatitis C Virus (HCV) Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections3
1CompletedTreatmentCandidiasis infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentMalignancies / Pain NOS1
1TerminatedSupportive CareNausea and vomiting / Pain NOS / Sleep disorders and disturbances / Unspecified Adult Solid Tumor, Protocol Specific1
1Unknown StatusBasic ScienceSubstance-Related Disorders1
1WithdrawnTreatmentKyphosis / Scoliosis1
1, 2CompletedBasic ScienceCritically-ill Patients / Premature Birth of Newborn1
1, 2CompletedTreatmentDisease, Chronic / Pain NOS / Prescription Opioid Abuse1
1, 2CompletedTreatmentOpiate Addiction1
1, 2CompletedTreatmentPain NOS1
2CompletedPreventionOpiate Addiction1
2CompletedSupportive CareIdiopathic Scoliosis1
2CompletedTreatmentCocaine-Related Disorders1
2CompletedTreatmentDependence, Cocaine / Opioid Dependence1
2CompletedTreatmentHeroin Dependence / Opioid-Related Disorders / Substance-Related Disorders1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Peripheral Neuropathy1
2CompletedTreatmentOpioid Dependence1
2CompletedTreatmentPain NOS2
2RecruitingBasic ScienceMaternal Opioid Use Disorder / Opioid Exposed Infant1
2RecruitingTreatmentDrug withdrawal syndrome neonatal1
2TerminatedTreatmentNeoplasms / Pain NOS1
2TerminatedTreatmentOpioid-Related Disorders1
2TerminatedTreatmentPain NOS1
2WithdrawnTreatmentHIV-associated Neuropathy / Polyneuropathies1
2, 3Unknown StatusTreatmentOpioid Dependence1
3Active Not RecruitingTreatmentDrug withdrawal syndrome neonatal / Neonatal Opioid Withdrawal1
3CompletedHealth Services ResearchScoliosis1
3CompletedPreventionHepatitis C Viral Infection / Methadone / Substance Dependence1
3CompletedTreatmentChronic Non-Malignant Pain1
3CompletedTreatmentCocaine-Related Disorders / Opioid-Related Disorders / Substance-Related Disorders1
3CompletedTreatmentHeroin Addiction1
3CompletedTreatmentHerpes Zoster / Pain NOS1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)1
3CompletedTreatmentMalignancies1
3CompletedTreatmentOpiate Addiction1
3CompletedTreatmentOpiate Dependent1
3CompletedTreatmentOpioid Dependence2
3CompletedTreatmentOpioid Dependence / Opioid Related Disorders / Pregnancy1
3CompletedTreatmentPost-Herpetic Neuralgia (PHN)1
3RecruitingSupportive CarePain, Intractable1
3RecruitingTreatmentOpioid Dependence1
3RecruitingTreatmentPain NOS / Scoliosis1
3TerminatedTreatmentCancer, Advanced / Tumors, Solid1
3Unknown StatusTreatmentOpiate Addiction1
3Unknown StatusTreatmentPain Related to Cancer1
4Active Not RecruitingTreatmentPostoperative pain1
4CompletedPreventionNausea and Vomiting, Postoperative / Postoperative pain1
4CompletedPreventionPain, Chronic / Postoperative pain1
4CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Opiate Addiction / Substance, Addiction1
4CompletedTreatmentAcute Postoperative Pain / Chronic Persistent Surgical Pain / Hydromorphone Use / Patients Satisfaction1
4CompletedTreatmentBack Pain Lower Back1
4CompletedTreatmentCancer of Head and Neck / Pain NOS1
4CompletedTreatmentDrug withdrawal syndrome neonatal2
4CompletedTreatmentHeroin Dependence1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Opioid-Related Disorders1
4CompletedTreatmentOpiate Addiction1
4CompletedTreatmentOpiate-Related Disorders1
4CompletedTreatmentPain, Chronic1
4CompletedTreatmentPain, Chronic / Postoperative pain1
4CompletedTreatmentPain, Neuropathic1
4CompletedTreatmentPostoperative pain1
4Not Yet RecruitingTreatmentOpioids Use / Postoperative pain1
4RecruitingHealth Services ResearchAddictions / Hepatitis / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) / Opioid Dependence / Tuberculosis Infection1
4RecruitingSupportive CareColon Diverticulosis / Colonic Neoplasms / Constipation Drug Induced / Diverticulitis, Colonic / Ileus / Ileus paralytic / Ileus; Mechanical / Malignant Neoplasm of Colon / Occasional Constipation / Postoperative pain / Rectum Cancer / Rectum Neoplasm1
4RecruitingTreatmentDrug withdrawal syndrome neonatal1
4RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Substance Related Disorders1
4RecruitingTreatmentLaminectomy1
4RecruitingTreatmentOpioid Use Disorders1
4RecruitingTreatmentPain NOS1
4RecruitingTreatmentPostoperative pain1
4RecruitingTreatmentThoracolumbar Scoliosis1
4TerminatedTreatmentChronic Hepatitis C Virus (HCV) Infection1
4TerminatedTreatmentNeuropathic Chronic Pain1
4Unknown StatusTreatmentDelirium / Opioid Use, Unspecified With Withdrawal / Opioid-Induced Disorders1
4Unknown StatusTreatmentFracture Bone / Postoperative pain1
4Unknown StatusTreatmentOpioids Use1
Not AvailableActive Not RecruitingHealth Services ResearchOpioid Use Disorders1
Not AvailableCompletedNot AvailableBreakthrough Cancer Pain / Pain, Cancer / Pain, Neuropathic / Tumors1
Not AvailableCompletedPreventionHeroin Addiction1
Not AvailableCompletedPreventionPost-Operative Nausea and Vomiting (PONV)1
Not AvailableCompletedSupportive CareHead and Neck Squamous Cell Carcinoma (HNSCC) / Pain NOS / Vesicular Stomatitis1
Not AvailableCompletedTreatmentAnaesthesia therapy1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentPain NOS / Spinal Cord Injuries (SCI) / Traumatic Amputations1
Not AvailableCompletedTreatmentPostoperative pain1
Not AvailableRecruitingOtherOpioid-Related Disorders / Pregnancy1
Not AvailableRecruitingSupportive CareStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8 / Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v81
Not AvailableRecruitingTreatmentAnaesthesia therapy / Post-Operative Pain1
Not AvailableRecruitingTreatmentMalignancies1
Not AvailableRecruitingTreatmentOpioid Use, Unspecified1
Not AvailableRecruitingTreatmentPain NOS1
Not AvailableRecruitingTreatmentPost Laparotomy Pain Treatment1
Not AvailableRecruitingTreatmentSickle Cell Disorders1
Not AvailableTerminatedNot AvailableOpioid-Related Disorders1
Not AvailableTerminatedSupportive CareBrain and Central Nervous System Tumors / Chronic Myeloproliferative Disorders / Leukemias / Lymphoproliferative Disorders / Malignant Lymphomas / Multiple Myeloma and Plasma Cell Neoplasm / Myelodysplastic Syndromes / Myelodysplastic/Myeloproliferative Neoplasms / Pain NOS / Precancerous Conditions / Unspecified Adult Solid Tumor, Protocol Specific1
Not AvailableTerminatedTreatmentPostoperative pain1
Not AvailableUnknown StatusNot AvailableOpiate Dependent / Previous Illicit Drug Use1
Not AvailableUnknown StatusDiagnosticPain, Chronic1
Not AvailableUnknown StatusTreatmentHeroin Dependence1
Not AvailableWithdrawnTreatmentOpiate Dependence1
Not AvailableWithdrawnTreatmentPostoperative pain1

Pharmacoeconomics

Manufacturers
  • Roxane laboratories inc
  • Vistapharm inc
  • Mallinckrodt chemical inc
  • Bioniche pharma usa llc
  • Sandoz inc
  • Mallinckrodt inc
  • The pharmanetwork llc
Packagers
  • AAIPharma Inc.
  • Bioniche Pharma
  • Blenheim Pharmacal
  • Bryant Ranch Prepack
  • D.M. Graham Laboratories Inc.
  • Direct Dispensing Inc.
  • Dispensing Solutions
  • Diversified Healthcare Services Inc.
  • Eon Labs
  • Lake Erie Medical and Surgical Supply
  • Mallinckrodt Inc.
  • Nucare Pharmaceuticals Inc.
  • Physicians Total Care Inc.
  • Redpharm Drug
  • Roxane Labs
  • Stat Rx Usa
  • Vistapharm Inc.
  • Xanodyne Pharmaceuticals Inc.
Dosage forms
FormRouteStrength
TabletOral1 mg
TabletOral10 mg
TabletOral25 mg
TabletOral5 mg
SolutionOral1 mg
Injection, solutionIntravenous10 mg/1mL
TabletOral40 mg/1
ConcentrateOral10 mg/1mL
Injection, solutionIntramuscular; Intravenous; Subcutaneous10 mg/1mL
PowderOral1 g/1g
SolutionOral10 mg/5mL
SolutionOral5 mg/5mL
TabletOral10 mg/1001
TabletOral10 mg/1
TabletOral5 mg/1001
TabletOral5 mg/1
SolutionOral10 mg
Prices
Unit descriptionCostUnit
Methadone hcl 10 mg/ml vial7.48USD ml
Methadone hcl powder5.91USD g
Metadol 25 mg Tablet1.69USD tablet
Metadol 10 mg Tablet0.9USD tablet
Methadone intensol 10 mg/ml0.85USD ml
Metadol 5 mg Tablet0.56USD tablet
Methadone hcl 10 mg tablet0.37USD tablet
Metadol Concentrate 10 mg/ml Liquid0.37USD ml
Methadone hcl 5 mg tablet0.34USD tablet
Dolophine hcl 10 mg tablet0.21USD tablet
Metadol 1 mg Tablet0.17USD tablet
Methadose 5 mg tablet0.16USD tablet
Methadose 10 mg tablet0.14USD tablet
Dolophine hcl 5 mg tablet0.13USD tablet
Metadol 1 mg/ml Solution0.1USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)235.0 °CNot Available
logP3.93HANSCH,C ET AL. (1995)
pKa8.94 (at 25 °C)PERRIN,DD (1965)
Predicted Properties
PropertyValueSource
Water Solubility0.0059 mg/mLALOGPS
logP4.14ALOGPS
logP5.01ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)19.79ChemAxon
pKa (Strongest Basic)9.12ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area20.31 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity97.27 m3·mol-1ChemAxon
Polarizability36.28 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier+0.9772
Caco-2 permeable+0.7841
P-glycoprotein substrateSubstrate0.6224
P-glycoprotein inhibitor IInhibitor0.7627
P-glycoprotein inhibitor IINon-inhibitor0.9101
Renal organic cation transporterNon-inhibitor0.5851
CYP450 2C9 substrateNon-substrate0.7822
CYP450 2D6 substrateNon-substrate0.7743
CYP450 3A4 substrateSubstrate0.66
CYP450 1A2 substrateInhibitor0.5312
CYP450 2C9 inhibitorNon-inhibitor0.864
CYP450 2D6 inhibitorInhibitor0.5449
CYP450 2C19 inhibitorNon-inhibitor0.8177
CYP450 3A4 inhibitorNon-inhibitor0.5507
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6586
Ames testNon AMES toxic0.946
CarcinogenicityCarcinogens 0.6315
BiodegradationNot ready biodegradable0.9888
Rat acute toxicity3.5250 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.947
hERG inhibition (predictor II)Inhibitor0.7606
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-00di-9310000000-d71659ee33e210178a79
GC-MS Spectrum - CI-BGC-MSsplash10-03di-0009000000-c583dd769bf5998ac160
Mass Spectrum (Electron Ionization)MSsplash10-00di-9210000000-7542d8c3f742c7713c13
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-03di-0029000000-43d5c8da88c1aa260682
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-31b8655a24b30962bd8c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01b9-0590000000-9894da52e88d32034318
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0940000000-fedb75bd4c80c6c4fea9
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0gb9-0940000000-a27b5f75aab7fac8931d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-1d4283f6dffa11b765e7
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0019000000-416fca50b212d00b968c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-ad95925610aed55afe91
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0aor-1980000000-6d4d0adc4c8db177eaad
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1920000000-0548504791642aa3b2e0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-2920000000-dd2ce03c02a54aa24f83
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-3910000000-1af5f56241eabde05700
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-03di-0019000000-015df6e52b9d5ebe5cb2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0091000000-b328f3740a7ca4485324
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0aor-0980000000-24074e0b5c722d7279c0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1920000000-5477eb89abafab290dd1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-2920000000-b4ffdf7888e464422c0c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-3910000000-6053da2e4586dbcae300
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-0863c3130ca5df5f25b6

Taxonomy

Description
This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Diphenylmethanes
Direct Parent
Diphenylmethanes
Alternative Parents
Aralkylamines / Gamma-amino ketones / Trialkylamines / Organopnictogen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Diphenylmethane / Aralkylamine / Gamma-aminoketone / Ketone / Tertiary amine / Tertiary aliphatic amine / Carbonyl group / Organooxygen compound / Organonitrogen compound / Amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
tertiary amine, benzenes, ketone (CHEBI:6807)

Targets

Details
1. Mu-type opioid receptor
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Voltage-gated calcium channel activity
Specific Function
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone...
Gene Name
OPRM1
Uniprot ID
P35372
Uniprot Name
Mu-type opioid receptor
Molecular Weight
44778.855 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Shi J, Hui L, Xu Y, Wang F, Huang W, Hu G: Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat. 2002 Apr;19(4):459-60. [PubMed:11933204]
  4. Kakko J, von Wachenfeldt J, Svanborg KD, Lidstrom J, Barr CS, Heilig M: Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. Biol Psychiatry. 2008 Jan 15;63(2):172-7. Epub 2007 Sep 11. [PubMed:17850768]
  5. Kvam TM, Baar C, Rakvag TT, Kaasa S, Krokan HE, Skorpen F: Genetic analysis of the murine mu opioid receptor: increased complexity of Oprm gene splicing. J Mol Med (Berl). 2004 Apr;82(4):250-5. Epub 2004 Jan 9. [PubMed:14991152]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Sotgiu ML, Valente M, Storchi R, Caramenti G, Biella GE: Cooperative N-methyl-D-aspartate (NMDA) receptor antagonism and mu-opioid receptor agonism mediate the methadone inhibition of the spinal neuron pain-related hyperactivity in a rat model of neuropathic pain. Pharmacol Res. 2009 Oct;60(4):284-90. doi: 10.1016/j.phrs.2009.04.002. Epub 2009 Apr 11. [PubMed:19717013]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor binding
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
Gene Name
CHRNA10
Uniprot ID
Q9GZZ6
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-10
Molecular Weight
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Opioid receptor activity
Specific Function
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine n...
Gene Name
OPRD1
Uniprot ID
P41143
Uniprot Name
Delta-type opioid receptor
Molecular Weight
40368.235 Da
References
  1. Gross ER, Hsu AK, Gross GJ: Acute methadone treatment reduces myocardial infarct size via the delta-opioid receptor in rats during reperfusion. Anesth Analg. 2009 Nov;109(5):1395-402. doi: 10.1213/ANE.0b013e3181b92201. [PubMed:19843777]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Deeb TZ, Sharp D, Hales TG: Direct subunit-dependent multimodal 5-hydroxytryptamine3 receptor antagonism by methadone. Mol Pharmacol. 2009 Apr;75(4):908-17. doi: 10.1124/mol.108.053322. Epub 2009 Jan 8. [PubMed:19131665]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Lipopolysaccharide receptor activity
Specific Function
Binds bacterial lipopolysaccharide (LPS) (PubMed:17803912, PubMed:17569869). Cooperates with TLR4 in the innate immune response to bacterial lipopolysaccharide (LPS), and with TLR2 in the response ...
Gene Name
LY96
Uniprot ID
Q9Y6Y9
Uniprot Name
Lymphocyte antigen 96
Molecular Weight
18545.345 Da
References
  1. Hutchinson MR, Lewis SS, Coats BD, Rezvani N, Zhang Y, Wieseler JL, Somogyi AA, Yin H, Maier SF, Rice KC, Watkins LR: Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences. Neuroscience. 2010 May 19;167(3):880-93. doi: 10.1016/j.neuroscience.2010.02.011. Epub 2010 Feb 21. [PubMed:20178837]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various hydrophobic ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and ava...
Gene Name
ORM2
Uniprot ID
P19652
Uniprot Name
Alpha-1-acid glycoprotein 2
Molecular Weight
23602.43 Da
References
  1. Herve F, Duche JC, d'Athis P, Marche C, Barre J, Tillement JP: Binding of disopyramide, methadone, dipyridamole, chlorpromazine, lignocaine and progesterone to the two main genetic variants of human alpha 1-acid glycoprotein: evidence for drug-binding differences between the variants and for the presence of two separate drug-binding sites on alpha 1-acid glycoprotein. Pharmacogenetics. 1996 Oct;6(5):403-15. [PubMed:8946472]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986]
  4. Boulton DW, Arnaud P, DeVane CL: A single dose of methadone inhibits cytochrome P-4503A activity in healthy volunteers as assessed by the urinary cortisol ratio. Br J Clin Pharmacol. 2001 Apr;51(4):350-4. [PubMed:11318772]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Lan T, Yuan LJ, Hu XX, Zhou Q, Wang J, Huang XX, Dai DP, Cai JP, Hu GX: Effects of CYP2C19 variants on methadone metabolism in vitro. Drug Test Anal. 2017 Apr;9(4):634-639. doi: 10.1002/dta.1997. Epub 2016 May 19. [PubMed:27199033]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A7
Uniprot ID
P24462
Uniprot Name
Cytochrome P450 3A7
Molecular Weight
57525.03 Da
References
  1. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Kharasch ED, Hoffer C, Whittington D, Sheffels P: Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther. 2004 Sep;76(3):250-69. [PubMed:15371986]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C8
Uniprot ID
P10632
Uniprot Name
Cytochrome P450 2C8
Molecular Weight
55824.275 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Catalyzes the formation of aromatic C18 estrogens from C19 androgens.
Gene Name
CYP19A1
Uniprot ID
P11511
Uniprot Name
Aromatase
Molecular Weight
57882.48 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Curator comments
Data supporting this enzyme action are limited to in vitro studies.
General Function
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP1A2
Uniprot ID
P05177
Uniprot Name
Cytochrome P450 1A2
Molecular Weight
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Ferrari A, Coccia CP, Bertolini A, Sternieri E: Methadone--metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004 Dec;50(6):551-9. doi: 10.1016/j.phrs.2004.05.002. [PubMed:15501692]
  3. Prost F, Thormann W: Capillary electrophoresis to assess drug metabolism induced in vitro using single CYP450 enzymes (Supersomes): application to the chiral metabolism of mephenytoin and methadone. Electrophoresis. 2003 Aug;24(15):2577-87. doi: 10.1002/elps.200305493. [PubMed:12900870]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C18
Uniprot ID
P33260
Uniprot Name
Cytochrome P450 2C18
Molecular Weight
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  2. Rendic S: Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448. [PubMed:11996015]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Stormer E, Perloff MD, von Moltke LL, Greenblatt DJ: Methadone inhibits rhodamine123 transport in Caco-2 cells. Drug Metab Dispos. 2001 Jul;29(7):954-6. [PubMed:11408360]
  2. Tournier N, Chevillard L, Megarbane B, Pirnay S, Scherrmann JM, Decleves X: Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int J Neuropsychopharmacol. 2010 Aug;13(7):905-15. doi: 10.1017/S1461145709990848. Epub 2009 Nov 4. [PubMed:19887017]

Drug created on June 13, 2005 07:24 / Updated on November 20, 2018 13:19